Thursday 22 October, 2020

One of the most aggressive forms of lung cancer is small cell lung cancer (SCLC), which is associated with an extremely poor prognosis. Surgery is not an option for SCLC patients, leaving chemotherapy and radiotherapy as the key current treatment. While immunotherapy has shown some early promise in treating lung cancer, it has had limited benefits when targeting SCLC.

Associate Professor Kate Sutherland from the WEHI is investigating why some patients are responding better to immunotherapy than others. To undertake this research, VCB is procuring high-quality tumour tissue and blood derivatives from SCLC patients.

The Victorian Cancer Biobank through the Cancer Council Victoria as Lead Agency is supported by the Victorian Government through the Victorian Cancer Agency, a business unit of the Department of Health.

RAP Victorian Cancer Biobank would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.

Jump to page top

Consortium members

Cancer Council Victoria Austin Health Eastern Health Monash Health Peter Mac Royal Melbourne Hospital

Supported by